Morgan Stanley: Hengrui Pharma's $15.2 Billion Partnership with BMS to Accelerate Global Expansion

Stock News05-13

Morgan Stanley has issued a research report highlighting a global strategic collaboration between Hengrui Pharma and Bristol Myers Squibb, covering 13 pre-clinical assets with a total transaction value of $15.2 billion. The deal includes a $600 million upfront payment, annual payments totaling $350 million between 2027 and 2028, up to $14.3 billion in milestone payments, and tiered sales royalties. The firm maintains Hengrui as its top pick in China's healthcare sector, assigning an "Overweight" rating with an H-share target price of HK$92. According to the report, this strategic partnership, encompassing multiple formats and asset modalities, further validates Hengrui Pharma's early-stage R&D platform and enhanced global capabilities. Beyond the near-term cash benefits, the bilateral collaboration structure and options for co-development and commercialization are expected to accelerate Hengrui's globalization efforts and generate commercial synergies for its expanding immunology portfolio in the Chinese market.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1100038164?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-13 11:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1100038164","market":"other","top_or_hot":-1,"title":"Morgan Stanley: Hengrui Pharma's $15.2 Billion Partnership with BMS to Accelerate Global Expansion","media":"Stock News","content":"<p>Morgan Stanley has issued a research report highlighting a global strategic collaboration between Hengrui Pharma and Bristol Myers Squibb, covering 13 pre-clinical assets with a total transaction value of $15.2 billion. The deal includes a $600 million upfront payment, annual payments totaling $350 million between 2027 and 2028, up to $14.3 billion in milestone payments, and tiered sales royalties. The firm maintains Hengrui as its top pick in China's healthcare sector, assigning an \"Overweight\" rating with an H-share target price of HK$92. According to the report, this strategic partnership, encompassing multiple formats and asset modalities, further validates Hengrui Pharma's early-stage R&D platform and enhanced global capabilities. Beyond the near-term cash benefits, the bilateral collaboration structure and options for co-development and commercialization are expected to accelerate Hengrui's globalization efforts and generate commercial synergies for its expanding immunology portfolio in the Chinese market.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Morgan Stanley: Hengrui Pharma's $15.2 Billion Partnership with BMS to Accelerate Global Expansion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMorgan Stanley: Hengrui Pharma's $15.2 Billion Partnership with BMS to Accelerate Global Expansion\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-05-13 11:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Morgan Stanley has issued a research report highlighting a global strategic collaboration between Hengrui Pharma and Bristol Myers Squibb, covering 13 pre-clinical assets with a total transaction value of $15.2 billion. The deal includes a $600 million upfront payment, annual payments totaling $350 million between 2027 and 2028, up to $14.3 billion in milestone payments, and tiered sales royalties. The firm maintains Hengrui as its top pick in China's healthcare sector, assigning an \"Overweight\" rating with an H-share target price of HK$92. According to the report, this strategic partnership, encompassing multiple formats and asset modalities, further validates Hengrui Pharma's early-stage R&D platform and enhanced global capabilities. Beyond the near-term cash benefits, the bilateral collaboration structure and options for co-development and commercialization are expected to accelerate Hengrui's globalization efforts and generate commercial synergies for its expanding immunology portfolio in the Chinese market.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0359202008.SGD","symbol_name":"Blackrock China Fund A2 SGD-H","start_time":0,"source_url":"","article_id":"1100038164","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1100038164","pubTimestamp":1778641225,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Morgan Stanley has issued a research report highlighting a global strategic collaboration between Hengrui Pharma and Bristol Myers Squibb, covering 13 pre-clinical assets with a total transaction...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600276":"恒瑞医药","LU0359202008.SGD":"Blackrock China Fund A2 SGD-H","LU1064130708.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC","LU2289578879.USD":"ALLIANZ CHINA A OPPORTUNITIES \"AT\" (USD) ACC","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU1997245177.USD":"安联神洲A股基金","LU1255011170.USD":"JPM CHINA A-SHARE OPPORTUNITIES \"A\" (USD) ACC","LU1023057109.AUD":"BGF CHINA \"A2\" (AUDHDG) ACC","LU2543165471.USD":"E FUND (HK) GLOBAL QUALITY GROWTH \"A\" (USD) ACC","01276":"恒瑞医药","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU2580892789.USD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (USD) ACC","LU1580142542.USD":"Blackrock Systematic China A-Share Opportunities A2 USD","BK0183":"MSCI概念","LU0359201612.USD":"贝莱德中国基金A2","BK0188":"融资融券","LU0405327148.USD":"ALLSPRING CHINA A FOCUS \"A\" (USD) ACC","LU1781817850.SGD":"Blackrock Systematic China A-Share Opportunities A2 SGD-H","BK0012":"证金概念","LU2097828557.USD":"AZ EQUITY CHINA \"A\" (USD) ACC","BK0028":"国家队","LU2097828631.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC","LU1997245094.SGD":"安联神州A股基金AT Acc SGD","BK1191":"制药","LU2495084118.USD":"ALLIANZ CHINA A-SHARES \"ATH\" (USDHDG) ACC","LU2097828714.EUR":"AZ EQUITY CHINA \"BAZ\" (EUR) ACC","LU1997244956.HKD":"ALLIANZ CHINA A-SHARES \"AT\" (HKD) ACC A","LU2580892862.HKD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (HKD) ACC","BK0060":"抗癌","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","LU2097828805.USD":"AZ EQUITY CHINA \"A-AZ\" (USD) ACC","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU0359201885.HKD":"BGF CHINA \"A2\" (HKD) ACC","LU1146622755.USD":"安本中国A股股票基金A Acc","LU0405327494.USD":"ALLSPRING CHINA A FOCUS \"I\" (USD) ACC","BK0196":"行业龙头","LU2097828474.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC A","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","BK0239":"医药制造","LU1820825898.SGD":"Aberdeen Standard SICAV I - China A Share Equity A Acc SGD-H","LU1655091616.SGD":"JPMorgan Funds - China A-Share Opportunities A (acc) SGD","BMS":"碧美斯","LU1328615791.USD":"FULLERTON LUX FUNDS - ALL CHINA EQUITIES \"I\" (USD) ACC"},"translate_title":"大摩：恒瑞医药152亿美元与BMS合作加速全球扩张","themeId":"d8fdac8d3d9097cb034fb43ab6bd5883","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600276":1,"BMS":1,"01276":1},"content_text":"Morgan Stanley has issued a research report highlighting a global strategic collaboration between Hengrui Pharma and Bristol Myers Squibb, covering 13 pre-clinical assets with a total transaction value of $15.2 billion. The deal includes a $600 million upfront payment, annual payments totaling $350 million between 2027 and 2028, up to $14.3 billion in milestone payments, and tiered sales royalties. The firm maintains Hengrui as its top pick in China's healthcare sector, assigning an \"Overweight\" rating with an H-share target price of HK$92. According to the report, this strategic partnership, encompassing multiple formats and asset modalities, further validates Hengrui Pharma's early-stage R&D platform and enhanced global capabilities. Beyond the near-term cash benefits, the bilateral collaboration structure and options for co-development and commercialization are expected to accelerate Hengrui's globalization efforts and generate commercial synergies for its expanding immunology portfolio in the Chinese market.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1100038164","isCrawlerRequest":true}